Drug Trial Radar · NCT06258746
Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.
Last checked: Nov 20, 2026Latest source record: Aug 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
6
Actual
Start
Dec 5, 2023
Primary completion
Dec 21, 2023
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Xizang Haisco Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK31679 in healthy male subjects.
Conditions
- Healthy
Interventions
[14C]HSK31679Drug
A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass balanceTime frame: From the start of administration to 240 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.